Differential expression of MMP and uPA systems and prognostic relevance of their expression in esophageal squamous cell carcinoma

International Journal of Cancer

Volumn 110, Issue 2, 2004, Pages 201-207

  Yamashita, Keishi ^a   Tanaka, Yoichi ^b   Mimori, Koshi ^a   Inoue, Hiroshi ^a   Mori, Masaki ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b Saitama Prefectural Cancer Center   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; MATRILYSIN; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLASMINOGEN ACTIVATOR; STROMELYSIN; STROMELYSIN 3;

ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL ARTICLE; CONTROLLED STUDY; ESOPHAGUS CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; CARCINOMA, SQUAMOUS CELL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MATRIX METALLOPROTEINASE 11; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MATRIX METALLOPROTEINASES, MEMBRANE-ASSOCIATED; METALLOENDOPEPTIDASES; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; URINARY PLASMINOGEN ACTIVATOR;

EID: 2342580668     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.20067     Document Type: Article

References (39)

1. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Sem Cancer Biol 2000;10:415-33.
2. Brinckerhoff CE, Matrisian LM. Matrix metalloproteinases: a tail of a frog that became a prince. Nat Rev Mol Cell Biol 2002;3:207-14.
3. Liotta LA, Tryggvason K, Garbisa S, Hart I, Foltz CM, Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-8.
4. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991;64:327-36.
5. Azzam HS, Arand G, Lippman ME, Thompson EW. Association of MMP-2 activation potential with metastatic progression in human breast cancer cell lines independently of MMP-2 production. J Natl Cancer Inst 1993;85:1758-64.
6. Sato H, Takino T, Okada Y, Cao J, Shinagawa A, Yamamoto E, Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994;370:61-5.
7. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Gene Dev 2000;14:163-76.
8. Yu W, Kim J, Ossowaki L. Reduction in surface urokinase receptor forces malignant cells into protracted state of dormancy. J Cell Biol 1997;137:767-7.
9. Yu WH, Woessner JF, Jr, McNeish JD, Stamencovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Gene Dev 2002;16:307-23.
10. Kim J, Yu K, Kovalski K, Ossowski L. Requirement for specific proteases in cancer cell intravasation as revealed by a novel semi-quantitative PCR-based assay. Cell 1998;94:353-62.
11. Sehgal G, Hua J, Bernhard EJ, Sehgal I, Thompson TC, Muschel RJ. Requirement for matrix metalloproteinase-9 (gelatinase B) expression in metastasis by murine prostate carcinoma. Am J Pathol 1998;152:5591-6.
12. Murray GI, Duncan ME, O'Neil P, McKay JA, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in oesophageal cancer. J Pathol 1998;185:256-61.
13. Yamashita K, Mori M, Kataoka A, Inoue H, Sugimachi K. The clinical significance of MMP-1 expression in oesophageal carcinoma. Br J Cancer 2001;84:276-82.
14. Shima I, Sasaguri Y, Kusukawa J, Yamana H, Fujita H, Kakegawa T, Morimatsu M. Production of matrix metalloproteinase-2 and metalloproteinase-3 related to malignant behavior of esophageal carcinoma: a clinicopathologic study. Cancer 1992;70:2747-53.
15. Yamashita K, Upadyay S, Mimori K, Inoue H, Mori M. Clinical significance of SPARC and its relation to esophageal carcinoma progression. Cancer 2003;97:2412-9.
16. Yamamoto H, Adachi Y, Itoh F, Iku S, Matsuno K, Kusano M, Arimura Y, Endo T, Hinoda Y, Hosokawa M, Imai K. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999;59:3313-6.
17. Yamashita K, Mori M, Shiraishi T, Shibuta K and Sugimachi K. Clinical significance of matrix metalloproteinase-7 expression in esophageal carcinoma. Clin Cancer Res 2000;6:1169-74.
18. Ohashi K, Nemoto T, Nakamura K, Nemori R. Increased expression of matrix metalloproteinase 7 and 9 and membrane type 1-matrix metalloproteinase in esophageal squamous cell carcinomas. Cancer 2000;88:2201-9.
19. Porte H, Triboulet JP, Kotelevets L, Carrat F, Prevot S, Nordlinger B, DiGioia Y, Wurtz A, Comoglio P, Gespach C, Chastre E. Overexpression of stromelysin-3, BM-40/SPARC, and MET genes in human esophageal carcinomas: implications for prognosis. Clin Cancer Res 1998;4:1375-82.
20. Torzewski M, Sarbia M, Verreet P, Dutkowski P, Heep H, Willers R, Gabbert H. Prognostic significance of urokinase-type plasminogen activator expression in squamous cell carcinomas of the esophagus. Clin Cancer Res 1997;3:2263-8.
21. Nekarda H, Schiegel P, Schmitt M, Stark M, Mueller JD, Fink U and Siewert JR. Strong prognostic impact of tumor-associated urokinase-type plasminogen activator in completely resected adenocarcinoma of the esophagus. Clin Cancer Res 1998;4:1755-63.
22. Shiomi H, Eguchi Y, Tani T, Kodama M, Hattori T. Cellular distribution and clinical value of urokinase-plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma. Am J Pathol 2000;156:567-75.
23. Mori M, Mimori K, Shiraishi T, Tanaka S, Ueo H, Sugimachi K, Akiyoshi T. p27 expression and gastric carcinoma. Nat Med 1997;3:593.
24. Babic MB, Tsao KM, Ho J, Pintilie M, Leco K, Chamberlain D, Shepherd FA. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small cell lung cancer. J Clin Oncol 1999;17:1802-8.
25. McVey JH, Nomura S, Kelly P, Mason U, Hogan BL. Characterization of the mouse SPARC/osteonectin gene. Intron/exon organization and an unusual promoter region. J Biol Chem 1988;263:11111-6.
26. Qin H, Sun Y, Benveniste EN. The transcription factors Sp1, Sp3, and AP-2 are required for constitutive matrix metalloproteinase-2 gene expression in astroglioma cells. J Biol Chem 1999;274:29130-7.
27. Lohi J, Lehti K, Valtanen H, Parks WC, Keski-Oja J. Structural analysis and promoter characterization of human membrane-type matrix metalloproteinase-1 (MT1-MMP) gene. Gene 2000;242:75-86.
28. Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb, Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenetic switch during carcinogenesis. Nat Cell Biol 2000;2:737-44.
29. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, Harper J, Tamvokopoulos G, Moses MA. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000;97:3884-9.
30. Fridman R, Toth M, Pena D, Mobashery S. Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995;55:2548-55.
31. Bayer Inc. Bayer holts clinical trials evaluating MMPI. http://www. bayerpharma.com/clinicaltrials/1999.
32. Takahashi M, Tsunoda T, Seiki M, Nakamura Y, Furukawa Y. Identification of membrane-type matrix metalloproteinase-1 as a target of the beta-catenin/ Tcf4 complex in human colorectal cancers. Oncogene 2002;21:5861-7.
33. Zhang D, Brodt P. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI3-kinase/Akt signaling. Oncogene 2003;22:974-82.
34. Powell SM, Papadopoulos N, Kinzler KW, Smolinski KN, Meltzer SJ. APC gene mutations in the mutation cluster region are rare in esophageal cancers. Gastroenterology 1994;107:1759-63.
35. Kawakami K, Brabender J, Lord RV, Groshen S, Greenwald BD, Krasna MI, Yin J, Fleisher AS, Abraham JM, Beer DG, Sidansky D, Huss HT, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2001;92:1805-11.
36. Yamashita K, Upadhay S, Osada M, Mohammad OH, Xiao Y, Mori M, Sato F, Meltzer SJ, Sidransky D. Pharmacological unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell. Carcinoma. Cancer Cell 2002;2:485-500.
37. Trommsdorff M, Gotthardt M, Hiesberger T, Shelton J, Stockinger W, Nimpf J, Hammer RE, Richardson JA, Herz J. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 1999;97:689-701.
38. Mao B, Wo W, Li Y, Hoppe D, Stannek P, Glinka A, Niehrs C. LDL-receptor-related protein 6 is a receptor for Dickkopf proteins. Nature 2001;411:321-5.
39. Ohkubo N, Lee YD, Morishima A, Terashima T, Kikkawa S, Tohyama M, Sakanaka M, Tanaka J, Maeda N, Vitek MP, Mitsuda N. Apolipoprotein E and reelin ligands modulate tau phosphorylation through an apolipoprotein E receptor/disabled-1/glycogen synthase kinase-3 beta cascade. FASEB J 2003;17:295-7.